<DOC>
	<DOC>NCT00098228</DOC>
	<brief_summary>The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.</brief_summary>
	<brief_title>Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Diagnosis of COPD Age 4075 years Smoking history Other serious disease Allergy to QAB149 Respiratory tract infection</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>COPD, adults, QAB149</keyword>
</DOC>